1. NF-κB
    Apoptosis
  2. RANKL/RANK
    Apoptosis
  3. sRANKL-IN-2

sRANKL-IN-2 

Cat. No.: HY-151346
Handling Instructions

sRANKL-IN-2 (Compound S3-05) is a selective and orally active soluble RANKL (sRANKL) inhibitor with an IC50 of 0.41 μM. sRANKL-IN-2 can be used for the research of osteoporosis.

For research use only. We do not sell to patients.

sRANKL-IN-2 Chemical Structure

sRANKL-IN-2 Chemical Structure

CAS No. : 2411216-42-5

Size Stock
100 mg   Get quote  
250 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

sRANKL-IN-2 (Compound S3-05) is a selective and orally active soluble RANKL (sRANKL) inhibitor with an IC50 of 0.41 μM. sRANKL-IN-2 can be used for the research of osteoporosis[1].

IC50 & Target

soluble RANKL[1]

In Vitro

sRANKL-IN-2 (Compound S3-05) (0.03-10 μM; 24 h) induces mature osteoclasts apoptosis and attenuates bone resorption in a dose-dependent manner[1].
sRANKL-IN-2 (0-10 μM; 14 days) increases cell proliferation and mineralization in mouse embryonic mesenchymal stem cell line C3H10T1/2 or human primary osteoblasts cells with osteogenic differentiation medium[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis[1]

Cell Line: Mature osteoclasts
Concentration: 0.03, 0.1, 0.3, 1, 3 and 10 μM
Incubation Time: 24 h
Result: Significantly increased apoptosis of mature osteoclasts with an EC50 of 0.53 μM.

Cell Proliferation Assay[1]

Cell Line: C3H10T12 cells
Concentration: 0.08, 0.28, 0.92, 3.03 and 10 μM
Incubation Time: 14 days
Result: Increased cell proliferation and mineralization in mouse embryonic mesenchymal stem cell line C3H10T1/2.
In Vivo

sRANKL-IN-2 (Compound S3-05) (10 mg/kg/d; i.g.; 12 weeks) shows anti-osteoporosis activity in ovariectomy rats[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female SD ovariectomy (OVX) rats[1]
Dosage: 10 mg/kg/d
Administration: Oral administraton, 12 weeks
Result: Reduced bone loss, improved trabecular osteoporosis parameters, increased the bone volume / total volume (BV/TV).
Animal Model: 28-week-old and 280 g∼370 g weight male SD (Sprague Dawley) rats[1]
Dosage: 10 mg/kg
Administration: Oral gavage (Pharmacokinetic Study)
Result: The pharmacokinetic parameters of sRANKL-IN-2[1]
sRANKL-IN-2
AUC (hr*μg/mL) 0.38 ± 0.23
Cmax (μg/mL) 0.06 ± 0.01
T1/2 (h) 10.62 ± 2.31
Molecular Weight

434.42

Formula

C18H18N4O7S

CAS No.
SMILES

O=C(C1=C(C)N=C(NC(/C(C(C)=O)=N/NC2=CC=C(O)C=C2C(O)=O)=O)S1)OCC

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
sRANKL-IN-2
Cat. No.:
HY-151346
Quantity:
MCE Japan Authorized Agent: